INS and Hyperglycemia: In vitro, low-dose GSK2606414 treatment increased glucose-stimulated insulin secretion (GSIS) levels and pancreatic islet insulin content in mouse and human islets, while in vivo treatment with GSK2656157 enhanced GSIS and alleviated hyperglycemia in an insulin-deficient mouse model(Kim et al. 2018, 2019).